Caplyta vs Latuda
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Caplyta | US Latuda |
|---|---|---|
| Generic name | lumateperone Unverified catalogue summary (Generic name) for Caplyta in US; not checked against current local product information. | lurasidone Unverified catalogue summary (Generic name) for Latuda in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Caplyta in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Latuda in US; not checked against current local product information. |
| Treats | Adult schizophrenia, bipolar I/II depression, major depression (add-on) Unverified catalogue summary (Treats) for Caplyta in US; not checked against current local product information. | Schizophrenia and depressive episodes associated with bipolar I disorder Unverified catalogue summary (Treats) for Latuda in US; not checked against current local product information. |
| Category | Mental Health Unverified catalogue summary (Category) for Caplyta in US; not checked against current local product information. | Mental Health Unverified catalogue summary (Category) for Latuda in US; not checked against current local product information. |
| Manufacturer | Intra-Cellular Therapies, Inc. (US distributor) Unverified catalogue summary (Manufacturer) for Caplyta in US; not checked against current local product information. | Sumitomo Pharma America, Inc. Unverified catalogue summary (Manufacturer) for Latuda in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Caplyta in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Latuda in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Caplyta in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Latuda in US; not checked against current local product information. |
| Est. TV ad spend | $130M | $85M |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Caplyta in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Latuda in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Caplyta or Latuda better?
This directory does not compare clinical effectiveness or safety. Listing Caplyta and Latuda together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Caplyta and Latuda?
The table shows catalogue identification and estimated advertising information for Caplyta and Latuda, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Caplyta has the larger estimated TV advertising budget of the two.